Monday, October 15, 2012

The Coming Storm in Biotech


The Coming Storm in Biotech
A storm is coming in Biotech.  This storm is born of the convergence of years of computer science, medical and societal forces.  This storm will play out over a period of decades but will fundamentally change the way we think about and deliver healthcare.

With Big Data, comes big responsibilities

The first megatrend driving this is the generation and management of data. This starts with the patient and the ever increasing personal and corporate spend on health awareness, wellness and the mining of traditional bio markers, advance genomics and proteomics in a metric driven, data hungry world.  People are paying ever closer attention to diet, exercise, cholesterol and environmental factors.  This has led to a generation of humans who welcome being monitored, poked, prodded and sampled at a dizzying rate to collect a personal corpus of actionable data.

When we think of Big Data in the traditional IT sense, it is defined by such sources as: machine exhaust, web traffic, the Twitter “Fire Hose” and “internet of things” e.g. smart-grid.  All of these IT and consumer generated data, although massive, are dwarfed by the amount of data that is generated from human biology.
The societal question is what do we do with this data.   What is the next generation of personalized, predictive medicine? Who pays for it?  Predictive medicine is the ability to predict and assign probabilities to likely events in your medical future.  It flies in the face and represents a radical departure from traditional medicine where the medical community is only engaged after something goes wrong.   Once something is determined to be wrong, the physician deploys a hunt and peck method of seeing what combination of drug therapies, formulae, dosage and delivery method gets you on the path to wellness without messing something else up.  One of the fundamental problems is that the entire medical eco-system and path to sustained wellness is predicated on the simple question “What’s wrong with you today?”  Imagine if the answer was “Nothing, I’m just here to make sure I stay healthy”.  How would they bill for the battery of test to 1) Give you a steady state of what your target health profile should look like and 2) Based of the battery of predictive tests, what should you do to maintain target health.  The irony of course is that in the long run, the economic benefit of preventative care far outweighs the trillions spent on a traditional “break-fix” mentality.

Waves of Change

The Biotech revolution will happen in three distinct waves. The first wave was the wave of EMR adoption.   This started in the early 2000’s and continues today. This wave was about two major vectors: 1) Digital records e.g. Basic Document Management displacing the paper chart, handwritten notes, prescription pads, sticky notes.  The promise was process efficiency, reduction of errors, lower malpractice insurance costs etc.  and 2) Enterprise and Supply Chain efficiency.  By using an EMR, Doctor Groups, hospitals and HMO’s had cross departmental and pan-facility visibility into patient care. Before EMR, patient records were locked up in best of breed silos and profit centers such as: radiology, pharmacy and emergency.  Like manufacturing ERP in the 90’s, EMR’s deliver an integrated flow of transactional related data on patient services, billing, payments, and relationships with critical suppliers etc.

The second wave of change was the rise of unstructured, non-relational data “big data” modalities. Like business intelligence and the analytic capabilities that appeared post the ERP era, this tipping point for transforming traditional EMR transactional efficiency to now include imaging, PACS, and output from next generation sequencing data.  The first step and opportunity area will be around the simple storage and access of this data and the potential blending of these unstructured sources with transactional EMR data to enable the physician to simply view these new modalities when making a clinical decision.  The analysis and insights derived from these data types will still come from experts in the supply chain e.g. radiologists, geneticists.  But the clinician will now be able to draw upon these data sources for targeted action.

The third and arguably most significant wave of change post the data collection and integration phase will be delivering actionable insight at scale.  In order to accomplish this, we must be ready for predictive analytics augmenting the role of the clinician.  Clinical healthcare analytic and decision platforms will need to be developed that perform the IT heavy lifting described below and deliver clear decisive recommendations for the clinician to then impart their expert opinion towards the optimal course of action.

Noname.jpg
Figure 1 – The three waves of change and opportunity

Change is often about convergence

In traditional IT, we see this explosion of data particularity the rise in No-SQL stores such as Hadoop and Mongo enabling massive horizontally scalable stores of unstructured data. Combining these web/machine generated data sources with OLTP structured relational data from traditional sources such as customer demographic data, buying patterns, we see real-time analytic engines being able to curve fit a likely algorithm, run the multivariate linear regression and fit a demand and profitability curve.  This is useful in the case of an online retail environment to custom tailor a promotion, A/B test it and launch the promo.  In Financial Services, we see this as the domain of the quant trading, hedge fund gurus developing algorithms that predict the minute changes in a commodity based on a myriad of related and seemingly unrelated data sources.
The above examples are great when it comes to selling more shoes or doing currency arbitrage, but the Holy Grail is still untapped.

The perfect storm of convergence is happening when you combine modern medicines ability to generate data at an unprecedented rate with IT’s ability to store, manage, analyze and combine this clinical data across a huge number of disparate sources and modalities.  The good news is that the processes are similar.  A thriving eco-system of entrepreneurs, investors, universities, incubators has already built the base platforms that can address the market of predictive medicine.

Figure 2 is a sample marketscape of traditional IT vendors that make up the various layers of the predictive analytics category. 
Figure 2 - Sample Data Science Marketscape of Traditional IT Vendors
Moving upper left to upper right starting with the raw data stores of relational and data stores optimized for analytic processing all the way to predictive analytic engines, dashboards and KPI’s.   Moving lower left to lower right, you have the important layers of cleansing normalization, MDM to visualization. 
This horizontal technology mapping illustrates the aggregation of 20+ years of traditional computer and data science thinking.  These are known market segments that anyone having spent a few years in the field would be able to grasp and apply to traditional data problems. This market landscape represents about $65B in annual middleware spend in 2012.[1]

The same analysis/mapping needs to be done in the context of healthcare.  The differences will be subtle such as: the source systems, modalities and density of the data across modalities. The good news is that most of the concepts and many of the horizontal layers will be the same. 

The Economics and Societal Readiness

The most important question that needs to be answered is that in industries like Retail, Financial Services, or the consumer web, businesses are willing to pay billions of dollars to track consumers, optimize spending or increase on-line conversion by one percent.  Such is not the case of predictive medicine.  The expensive advanced testing required in building up a personal knowledge of one’s health profile remain by and large not covered by health insurance and therefore out of reach of the common person.  This requires a fundamental overhaul and perspective on how we look at preventative, quantitatively driven healthcare.
The clinical readiness is the transition from a largely human based intuitive decision making process to one that is on the sliding scale of augmented to highly predictive.  It is this evolution towards the clinician taking full advantage and improving their own judgment and reliability with predictive data based algorithms that will be the tipping point of acceptance and adoption. As with most mega-trends, this evolution will start locally and spread globally.  In early 2012, India instituted a nationwide program issuing a Unique Identification Number (UID) to all of their 1.2 billion residents. Each of the numbers will be tied to the biometric data of the recipient using three different forms of information – fingerprints, iris scans, and pictures of the face. All ten digits of the hand will be recorded, and both eyes will be scanned.  We’re only beginning to comprehend the repercussion of such a societal orchestration.

During our daily lives in the US, we are bombarded with predictive analytics looking to monitor, optimize and recommend action, either opt-in, prescribed our automated. Our lives are increasingly and subtlety controlled by such everyday events like variable HOV toll changes based on real-time traffic patterns or the perfectly timed coupon that magically appears in a banner add on Amazon.  These are but a few examples of everyday human behavior being measured, optimized and guided by deep data analysis.

The tipping point in health care will come equally as stealthy as our societal acceptance masked as the new era of customer service evolves over time.


Copyright 2012: Kevin Chew



[1] U.S. Tech Market Outlook for 2012 from Forrester Research

Amazon, Walmart, eBay, Groupon, Intuit, Square: it’s all about mobile payments


Amazon, Walmart, eBay, Groupon, Intuit, Square: it’s all about mobile payments.

As Amazon does auctions, eBay and Walmart are both transforming itself into a general marketplace like Amazon. 

Intuit is trying to monetize it’s SMB franchise, channel and direct sales capacity with Quickbooks and Square continues to march on by giving out it’s free mag readers and buying tremendous marketing air-time.

The question is what’s at stake here?  The answer is simple, the hearts, minds and wallet share of commerce (eCommerce and Bricks and Mortar) as we know it.  That’s all
My wife was looking for a new ottoman for her office. We went to the traditional B&M retailers found nothing.  Ended up buying it on Overstock.com.  Free shipping, better price, great reviews, great product, no sales tax.  All and all a great experience and without having to deal with a furniture sales person.

B&M retailers’ likeTarget and Walmart offer and sell more stuff from their websites than they do in their stores.  And for good reason, no inventory carrying costs, no stale merchandise, no sales clerks, no floor space.  Because of advanced web personalization, they know infinitely more about you as an online shopper than they will ever know about you as some schmo who walks into a store.  They can use that intelligence to target, personalize and up sell at will without somebody in a red vest laying a guilt trip and asking you if you want to donate to breast cancer today.

But why mobile payments?  2.75% is why.  There’s a whole underground economy that today is not participating in credit cards.  Cab drivers, hairstylists, street vendors that is they had an easy to use, and relatively painless way to collect credit cards they would.

I personally would love to have access to my Paypal account that I already use to pay for stuff on eBay and virtually every other website that takes it at my disposal when I buy and sell stuff in person. 

Copyright 2012: Kevin Chew